- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC
September 10th 2025, 10:24pm
ESMO Gastrointestinal Cancers Congress
Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.
Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors
September 10th 2025, 7:00pm
IASLC World Conference on Lung Cancer
Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.
Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy
September 10th 2025, 4:30pm
OncLive News Network: On Location at WCLC 2025
Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting
September 10th 2025, 2:00pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC
September 10th 2025, 1:00pm
IASLC World Conference on Lung Cancer
Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.
Cemiplimab Plus Chemotherapy Provides Long-Term Survival Benefit in Advanced NSCLC
September 10th 2025, 11:00am
IASLC World Conference on Lung Cancer
Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.
Dr Xia on the Differences Between ctDNA Monitoring Strategies in MET Exon 14–Mutant NSCLC
September 9th 2025, 8:03pm
IASLC World Conference on Lung Cancer
Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.
Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC
September 9th 2025, 7:53pm
IASLC World Conference on Lung Cancer
Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.
Firmonertinib Demonstrates Antitumor Activity, CNS Responses in EGFR PACC–Mutated NSCLC
September 9th 2025, 6:32pm
IASLC World Conference on Lung Cancer
Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.
Double-Dose Firmonertinib Showing Promising Activity in First-Line EGFR L858R–Mutated NSCLC
September 9th 2025, 4:54pm
IASLC World Conference on Lung Cancer
Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.
Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari
September 9th 2025, 4:15pm
OncLive News Network: On Location at WCLC 2025
Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Pooled Analysis Shows Manageable Safety Profile With Tepotinib in MET Exon 14+ NSCLC
September 9th 2025, 3:30pm
IASLC World Conference on Lung Cancer
Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.
SKYSCRAPER-05 Data Confirm Surgical Feasibility After Perioperative Tiragolumab Combo in NSCLC
September 9th 2025, 12:00pm
IASLC World Conference on Lung Cancer
The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.
Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC
September 8th 2025, 9:26pm
IASLC World Conference on Lung Cancer
Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.
Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology
September 8th 2025, 9:13pm
IASLC World Conference on Lung Cancer
Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.
Tepotinib Generates Superior Responses in Adenocarcinoma vs Non-Adenocarcinoma MET Exon 14 Skipping NSCLC
September 8th 2025, 9:04pm
IASLC World Conference on Lung Cancer
Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.
Final Analysis of Perioperative Tislelizumab Plus Chemotherapy Shows Sustained OS and EFS Improvement in Resectable NSCLC
September 8th 2025, 8:37pm
IASLC World Conference on Lung Cancer
Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.
ABBV-706 Yields Durable Responses and Is Deemed Tolerable in R/R SCLC
September 8th 2025, 7:12pm
IASLC World Conference on Lung Cancer
The SEZ6-targeting ADC ABBV-706 generated durable efficacy outcomes comparable with those of first-line SOC in patients with relapsed/refractory SCLC.
Signatera Genome Assay Demonstrates Strong Prognostic Value in Early-Stage Resectable NSCLC
September 8th 2025, 7:05pm
IASLC World Conference on Lung Cancer
A correlation between ctDNA negativity in the post-surgical MRD window and improved RFS and OS was observed with the Signatera Genome assay in NSCLC.
Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases
September 8th 2025, 6:24pm
IASLC World Conference on Lung Cancer
Dato-DXd demonstrated CNS PFS and ORR benefits vs docetaxel in patients with NSCLC with brain metastases.